New Therapeutic Approaches to Malignant Melanoma
|
|
- Roger Charles
- 5 years ago
- Views:
Transcription
1 2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA
2 Disclosure I have nothing to disclose. Off Label/Investigational Discussion In accordance with Annenberg Center policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.
3 Question #1 A 53 yo female with BRAF wild-type metastatic melanoma to the lungs, bone, and brain comes to see you for a consultation regarding treatment. A single lesion in the right parietal lobe was recently treated with stereotactic radiosurgery. What aspects of her care should be discussed with this patient?
4 Question #1 A. Radiation therapy has been shown to decrease T cell function, so should not be done prior to immune therapy B. Ipilimumab, pembrolizumab, and nivolumab have not been effective in patients with CNS metastases as the antibodies do not cross over into the CNS. CNS is a common site for progression with checkpoint blockade. C. Clinical responses to anti-pd1 are frequently delayed D. Pneumonitis inflammation of the lung is a potentially serious and fatal side effect to anti-pd-1 therapy and requires both radiographic and clinical close follow up. E. High grade diarrhea due to inflammatory colitis is common with anti-pd-1 and should be treated with oral steroids tapered over 1-2 weeks
5 Question #2 A 64 yo man with metastatic melanoma is being treated with dabrafenib (BRAFi) plus trametinib (MEKi). He reports high grade fevers to 104 o F. What treatment management should be considered?
6 Question #2 A. High grade fevers are a common intolerant adverse event, and progression frequently occurs do to this. Consider holding both drugs. Add short course of steroids as needed. B. Hold the trametinib as continued treatment with BRAFi (dabrafenib) is most important. Add short course of steroids as needed. C. Hold the dabrafenib as the addition of trametenib leads to fever. Add short course of steroids as needed. D. Fevers indicate an immune response from treatment. Consider adding immune checkpoint blockade. E. High fevers usually preclude a rash/skin toxicity. Examine the patient closely. Consider holding both drugs. Add short course of steroids as needed.
7 Melanoma The Problem Incidence in US rising faster than any other cancer Approximately 60,000 new cases in US; 8,000 deaths Incidence varies by region US: 15/100,000 New South Wales Australia: 1 in 20
8 Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) to Treat Melanoma T-cell activation T-cell inhibition T-cell potentiation T cell T cell T cell APC TCR MHC CD28 B7 CTLA4 APC TCR MHC CD28 B7 CTLA4 CD28 APC TCR MHC CD28 B7 X CTLA4 Antibody binds CTLA-4 Wolchok et al., Ann NY Acad Sci, 2013
9 MDX010-20: Melanoma Study Design Screening Induction > 1 Re-induction in eligible patients Previosly treated HLA-A*0201 positive Pre-treated CNS metastases allowed R A N D O M I Z E Ipilimumab (3 mg/m2 IV q3wks X 4 doses) + gp100 Ipilimumab (3 mg/m2 induction) + placebo gp100 + placebo R E I N D U C E Ipi + gp100 Ipi + placebo gp100 + placebo Follow-up Hodi et al. NEJM 2010
10 Survival Rate Ipilimumab + gp100 Ipilimumab alone gp100 alone 1-yr 44% 46% 25% 2-yr 22% 24% 14%
11 Potential Side Effects in Melanoma Patients Any Grade >Grade3 Dermatitis 40% 3% Diarrhea/Colitis 30% 8% Hypophysitis/Thyroiditis 6% 1% Hepatitis and Pancreatitis 9% 6% Other 6% 2% Nephritis Uveitis or Episcleritis Neuritis Overall 70% 20% IRAEs can be waxing and waning
12 Re-induction: Eligibility Criteria Signs of clinical benefit Patients with progression after: Stable disease of 6 months duration (from baseline) or Confirmed objective response (PR or CR) Acceptable safety No grade 3 iraes No grade 4 toxicity
13 Best Overall Response Rate at induction Ipi+gp100 Ipi gp100 PR SD PD SD PR Time to Re-induction and Follow-up PR SD Induction Re-induction: #1 #2 #3 * Ongoing x Dead x * * x * * * * * * x x * x x * x x * * x * * * x * * * * YEARS * * * * * * * * *
14 Primary Analysis of Pooled OS Data: 1861 Patients Median OS (95% CI): 11.4 ( ) Proportion Alive year OS Rate (95% CI): 22% (20 24%) Ipilimumab CENSORED Months Patients at Risk Ipilimumab Schadendorf et al.jco 2015
15 Conclusions Ipilimumab is the first drug to demonstrate prolonged survival in a randomized trials in patients with metastatic melanoma Ipilimumab represents a new class of potent targeted T-cell stimulants Activity first/second line (following XRT, chemo, IL-2) and CNS disease Provides long-term survival benefit for a subset of patients
16 Role of PD-1 in Suppressing Antitumor Immunity Activation (cytokines, lysis, prolif., migration) APC T cell B7.1 CD28 MHC-Ag TCR Signal 1 PD-1 (-) (-) (-) Tumor PD-L1 Inhibition (anergy, exhaustion, death) Tumor Keir ME et al, Annu Rev Immunol 2008; Pardoll DM, Nat Rev Cancer 2012
17 Role of PD-1 in Suppressing Antitumor Immunity Activation (cytokines, lysis, prolif., migration) APC T cell B7.1 CD28 MHC-Ag Tumor TCR Signal 1 PD-1 PD-L1 Inhibition (anergy, exhaustion, death) (-) (-) Tumor (-) Anti- PD-1 Keir ME et al, Annu Rev Immunol 2008; Pardoll DM, Nat Rev Cancer 2012
18 Nivolumab: Changes in Target Lesions Over Time in Melanoma Patients 1 mg/kg Dose administered IV Q2wk
19 Drug-Related Adverse Event Nivolumab Adverse Events All Grades Grades 3-4 Tot Pop* MEL Tot Pop MEL No. (%) of Patients, All Doses Any adverse event 207 (70) 82 (79) 41 (14) 21 (20) Fatigue 72 (24) 30 (29) 5 (2) 2 (2) Rash 36 (12) 21 (20) Diarrhea 33 (11) 18 (17) 3 (1) 2 (2) Pruritus 28 (9) 15 (14) 1 (0.3) Nausea 24 (8) 9 (9) 1 (0.3) 1 (1) Appetite 24 (8) 7 (7) Hemoglobin 19 (6) 7 (7) 1 (0.3) 1 (1) Pyrexia 16 (5) 5 (5) *AEs occurring in 5% of the total population. Common grade 3-4 AEs also included lymphopenia (3 pts) and abdominal pain and lipase increased (2 each). An additional 27 grade 3-4-related AEs were observed and one or more occurred in a single patient. Topalian et al. NEJM 2012
20 Nivolumab Overall Survival at 5 Years of Follow-up All Patients (events: 69/107), median and 95% CI: 17.3 ( ) NIVO 3 mg/kg (events: 11/17), median and 95% CI: 20.3 (7.2 NR) Probability of Survival Months Number of Patients at Risk All Patients NIVO 3 mg/kg Hodi AACR
21 Pembrolizumab (MK3475) is a Humanized IgG4, High-Affinity Anti-PD-1 Blocking Antibody Melanoma: Led to approval in ipilimumab refractory, prior BRAFi population: 173 patients 2 mg/kg Q 3 weeks 24% response rate Hamid O et al. N Engl J Med DOI: /NEJMoa
22 Rapid and Durable Changes in Target Lesions in Melanoma Change in target lesions from baseline (%) 1 mg/kg nivolumab + 3 mg/kg ipilimumab First occurrence of new lesion Weeks since treatment initiation A 52-year-old patient presented with extensive nodal and visceral disease Baseline LDH was elevated (2.3 x ULN); symptoms included nausea and vomiting Within 4 wk, LDH normalized and symptoms resolved At 12 wk, there was marked reduction in all areas of disease as shown Wolchok et al. NEJM 2013 Pretreatment 12 weeks At MTD 2 yr OS 88%
23 Nivolumab plus Ipilimumab Treatment-Related Select Adverse Events Occurring in 1 Patient Select Adverse Event Number of Patients (%) Concurrent Regimen All Cohorts (n=53) Sequenced Regimen All Cohorts (n=33) All Gr Gr 3-4 All Gr Gr 3-4 Pulmonary 3 (6) 1 (2) 1 (3 ) 0 Renal 3 (6) 3 (6) 0 0 Endocrinopathies 7 (13) 1 (2) 3 (9) 2 (6) Uveitis 3 (6) 2 (4) 0 0 Skin 37 (70) 2 (4) 8 (24) 0 Gastrointestinal 20 (38) 5 (9) 3 (9) 0 Hepatic 12 (23) 8 (15) 1 (3) 0 Infusion reaction 1 (2) Lipase 10 (19) 7 (13) 4 (12) 2 (6) Amylase 8 (15) 3 (6) 1 (3) 1 (3) Presented by: Jedd D. Wolchok, MD, PhD
24 24 CA : Study Design CA : Study Design Randomized, double-blind, phase III study to compare NIVO+IPI or NIVO alone to IPI alone* Stratify by: N=314 NIVO 1 mg/kg + IPI 3 mg/kg Q3W for 4 doses then NIVO 3 mg/kg Q2W Unresectable or Metatastic Melanoma Previously untreated 945 patients Randomize 1:1:1 BRAF mutation status AJCC M stage Tumor PD-L1 expression <5% vs 5%* N=316 NIVO 3 mg/kg Q2W + IPI-matched placebo Treat until progression or unacceptable toxicity Co- Primary endpoints: PFS and OS vs IPI Secondary endpoints: ORR, NIVO vs NIVO+IPI (OS and PFS)*, Safety N=315 *The study was not powered for a comparison between NIVO and NIVO+IPI IPI 3 mg/kg Q3W for 4 doses + NIVO-matched placebo Database lock: Sept 13, 2016 (median follow-up ~30 months in both NIVO-containing arms)
25 25 Melanoma Overall Survival Overall Percentage Survival of PFS (%) NIVO+IPI (N=314) NIVO (N=316) IPI (N=315) Median OS, months (95% CI) NR NR (29.1 NR) 20.0 ( ) HR (98% CI) vs. IPI 0.55 ( )* 0.63 ( ) -- 73% HR (95% CI) vs. NIVO 0.88 ( ) *P< % 67% 64% 59% 45% NIVO+IPI NIVO IPI Months Number of patients at risk: NIVO+IPI NIVO IPI Wolchok JD et al. NEJM 2017
26 26 Melanoma OS by Tumor PD-L1 Expression, 5% Cutoff Tumor PD-L1 Expression Level <5% Tumor PD-L1 Expression Level 5% NIVO+IPI NIVO IPI NIVO+IPI NIVO IPI Median OS, mo (95% CI) HR (95% CI) vs NIVO NR (31.8 NR) 0.84 ( ) NR (23.1 NR) 18.5 ( ) Median OS, mo (95% CI) HR (95% CI) vs NIVO NR 1.05 ( ) NR 28.9 (18.1 NR) % OS (%) % 55% OS (%) % 54% 30 41% NIVO+IPI NIVO IPI Months Number of patients at risk: NIVO+IPI NIVO IPI Months Number of patients at risk: NIVO+IPI NIVO IPI Wolchok JD et al. NEJM 2017
27 Management of Inflammatory Adverse Events Algorithms Diarrhea/Colitis High grade/prolonged low grade Rule out other causes/endoscopy, IV steroids, slow taper (e.g. 1 month), infliximab for refractory cases Hepatitis: Follow LFTs, pancreatic enzymes High grade: steroids, mycophenylate Pneumonitis Asymptomatic infiltrate vs. symptom (cough, SOB) Rule out other causes (e.g. flu); hold drug vs. steroids, infliximab resistant cases Endocrinopathies clinical suspicion, pituitary and thyroid
28 Conclusions Blockade of the PD-1 pathway represents a new immune therapy for patients with melanoma Preliminary data correlating PD-L1 expression in pretreatment tumor biopsies with clinical outcomes Pembrolizumab and Nivolumab are approved Nivolumab+ Ipilimumab approval PD-1 based treatment considered front-line therapy Algorithms for management of inflammatory adverse events Further combinations under development
29 Downstream signaling events: The MAPK pathway R R Plasma membrane K K Ras Raf MEK RAS mutations: 15% cancers, 90% pancreat (farnesyl transferase inhibitors) BRAF mutations: 66% malignant melanomas (Davies and Futreal, Nature 2002) Erk Proliferation
30 Selective BRAFi Vemurafenib PET and CT Responses Flaherty et al. NEJM 2010
31 Phase III BRIM3 Study design Screening BRAF V600E mutation Vemurafenib 960 mg po bid (N=337) Stratification Stage ECOG PS (0 vs 1) LDH level ( vs nl) Geographic region No active CNS disease Randomization N=675 Dacarbazine 1000 mg/m 2 iv q3w (N=338) Chapman NEJM 2011
32 Melanoma Progression-Free Survival and Overall Survival Chapman PB et al. N Engl J Med 2011;364:
33 Conclusions Selective BRAF inhibitors are a breakthrough for melanoma Benefit seen in all subgroups and baseline characteristics Despite a 50-80% response rate, vast majority of patients recur and develop resistance
34 BRAFi Mechanisms of Resistance Luke and Hodi, The Oncologist
35 BRAFi + MEKi: Melanoma Overall Survival Improved Dabrafenib (BFAFi) + Trametinib (MEKi) Overall Survival Increased incidence of pyrexia Decreased incidence of skin manifestations of BRAFi Robert C et al. N Engl J Med 2015;372:30-39.
36 Vemurafenib (BRAFi) + Cobimetinib (MEKi) Improves Melanoma Survival Larkin J et al. N Engl J Med 2014;371:
37 BRAF Targeted Therapy Side effects: rash, arthritis, diarrhea, squamous cell skin cancer, keratoacanthoma, photosensitivity, LFTs, prolonged QTc FDA approved for unresectable or stage IV melanoma with BRAF V600E (Dabrafenib + Trametinib, Vemurafenib + Cobimetinib) Not indicated for wild type BRAF Secondary skin cancers: paradoxical activation of MAPK in HRAS mutated keratinocytes Pyrexia and less skin toxicity with BRAFi + MEKi combination
38 What to do for a patient with BRAF mutated melanoma? Immune Therapy vs. Targeted Therapy PD-1 based therapy front-line regardless of BRAF status Immune combo vs. PD-1 alone Efficacy weighed with potential side effects Biomarker: PD-L1 expression? After PD-1 based therapy Targeted therapy vs Ipilimumab alone (if not get previously) Clinical trials/further data maturation to guide
39 Does the benefit of immune and targeted therapies in the metastatic setting offer benefit for adjuvant patients?
40 EORTC 18071/CA : Study Design High-risk, stage III, completely resected melanoma N=951 N=475 R N=476 INDUCTION Ipilimumab 10 mg/kg Q3W X4 INDUCTION Placebo Q3W X4 MAINTENANCE Ipilimumab 10 mg/kg Q12W up to 3 years MAINTENANCE Placebo Q12W up to 3 years Week 1 Week 12 Week 24 Stratification factors: Treatment up to a maximum 3 years, or until disease progression, intolerable toxicity, or withdrawal Stage (IIIA vs IIIB vs IIIC 1-3 positive lymph nodes vs IIIC 4 positive lymph nodes) Regions (North America, European countries and Australia) Eggermont et al. Lancet Oncology 2015
41 Overall Survival 4 Eggermont et al NEJM 2016
42 CA : CA : Study Design Study Design Patients with high-risk, completely resected stage IIIB/IIIC or stage IV melanoma Stratified by: 1:1 n = 453 n = 453 1)Disease stage: IIIB/C vs IV M1a-M1b vs IV M1c 2)PD-L1 status at a 5% cutoff in tumor cells NIVO 3 mg/kg IV Q2W and IPI placebo IV Q3W for 4 doses then Q12W from week 24 IPI 10 mg/kg IV Q3W for 4 doses then Q12W from week 24 and NIVO placebo IV Q2W Follow-up Maximum treatment duration of 1 year Enrollment period: March 30, 2015 to November 30,
43 Recurrence-free Survival, According to Disease Stage. Weber J et al. N Engl J Med DOI: /NEJMoa
44 Recurrence-free Survival in the Intention-to-Treat Population and According to Tumor PD-L1 Expression. Weber J et al. N Engl J Med DOI: /NEJMoa
45 45 Combi-AD: Study design Key eligibility criteria Completely resected, high-risk stage IIIA (lymph node metastasis > 1 mm), IIIB, or IIIC cutaneous melanoma BRAF V600E/K mutation Surgically free of disease 12 weeks before randomization ECOG performance status 0 or 1 No prior radiotherapy or systemic therapy Stratification BRAF mutation status (V600E, V600K) Disease stage (IIIA, IIIB, IIIC) R A N D O M I Z A T I O N N = 870 1:1 Treatment: 12 months a Dabrafenib 150 mg BID + trametinib 2 mg QD (n = 438) 2 matched placebos (n = 432) Followup b until end of study c Primary endpoint: RFS d Secondary endpoints: OS, DMFS, FFR, safety Long GV et al. NEJM 2017
46 Relapse-free Survival and Overall Survival. Long GV et al. NEJM 2017
47 Treatment options for patients with Stage III melanoma Observation IFN Participation in a clinical trial Ipiluminab (antictla4) clinical trials EORTC Ipilimumab vs. observation ECOG study Ipilimumab vs. high dose IFN Nivolumab (short follow-up) Dabrafenib plus Trametinib
48 Melanoma Treatment Advances Future is Fast Paced Immune modulation CTLA-4 Blockade PD-1 Blockade CTLA-4 + PD-1 Blockades PD-1 based therapy front-line Ipilimumab considered following PD-1 Improved genetic understanding BRAFi + MEKi Sequencing: Immune Therapy vs. Targeted Therapy Adjuvant Therapies: Immune therapy attractive Interferon vs Ipilimumab; Nivolumab; Dabrafenib/Trametinib Longer follow up
49 Disclosures and Questions Advisor Novartis, Merck Non-paid Advisor and/or Research Support Bristol-Myers Squibb, Genentech Questions:
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationTreatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC
Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationApproaches To Treating Advanced Melanoma
Approaches To Treating Advanced Melanoma Suraj Venna, MD Medical Director, Melanoma and Cutaneous Oncology Inova Schar Cancer Institute Associate Professor, VCU Fairfax VA Disclosures No relevant disclosures
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationEvolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures
Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes Fall Managed Care Forum November 11, 2016 Matthew Taylor, M.D. Disclosures Consulting/Advisory
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationBlack is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)
Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove) Provincial Cancer Care Conference 2018 Ralph P.W. Wong MD FRCPC St Boniface Site Director
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationMelanoma- Fighting the Dark Side
Melanoma- Fighting the Dark Side Anna C. Pavlick, BSN, MSc, DO, MBA Professor of Medicine and Dermatology Director, NYU Melanoma Program Director, NYU Clinical Trials Office NYU Perlmutter Cancer Center
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationUpdates in Metastatic Melanoma
SCSHP 214 Annual Meeting Updates in Metastatic Melanoma LeAnn B. orris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of Pharmacy Background Estimated 76,69 new cases in 213 Increasing
More informationHeme Onc Today New York Melanoma Meeting March 22-23, 2013 PD-1 antibodies
Heme Onc Today New York Melanoma Meeting March 22-23, 2013 PD-1 antibodies Jeffrey Weber Moffitt Cancer Center Tampa, FL Disclosures I have consulted for BMS, Merck, Genentech and GSK for Ad Boards and
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationNew Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy
New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationPhase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma
Phase 1 Study Combining Anti-PD-L1 (MEDI4736) With BRAF (Dabrafenib) and/or MEK (Trametinib) Inhibitors in Advanced Melanoma Abstract #3003 Ribas A, Butler M, Lutzky J, Lawrence D, Robert C, Miller W,
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationReview of immunotherapy in melanoma
Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationOverall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationImmunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto
Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationToxicity of Systemic Melanoma Therapies. Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney
Toxicity of Systemic Melanoma Therapies Alex Guminski Melanoma Institute Australia Royal North Shore Hospital University of Sydney Disclosures Advisory Board Novartis, BMS, Sanofi, Pfizer Travel support
More informationMelanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1
Presentation 1 The following is a transcript from a web-based CME -certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationA Case Study: Ipilimumab in Pre-treated Metastatic Melanoma
A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationOptimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma
Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationPembrolizumab: First in Class for Treatment of Metastatic Melanoma
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Pembrolizumab: First in Class for Treatment of Metastatic Melanoma CARRIE BARNHART, PharmD From Billings Clinic Cancer Center, Billings, Montana
More informationASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018
ASCO / COLUMBUS ENCORE PRESENTATION June 4, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the Private
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationNew treatments in melanoma
New treatments in melanoma Paolo A. Ascierto, MD Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine
More informationOverall Survival (OS) Analysis From an Expanded Access Program (EAP) of Nivolumab (NIVO) in Combination with Ipilimumab (IPI) in Patients with Advanced Melanoma (MEL) David Hogg, Paul B. Chapman, 2 Mario
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationMelanoma: Early Detection and Therapeutic Progress
Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures:
More informationUpdate on Melanoma Treatment. Tara C Mitchell, MD
Update on Melanoma Treatment Tara C Mitchell, MD Overview Immune therapy update Targeted therapy update New concepts in treating melanoma What is the immune system? A complex network of protective cells
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationEmerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD
Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma Evan J. Lipson, MD Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center April 25, 2014
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationOne Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD
One Moment Please One Moment Please Skin Cancer Thomas Olencki, DO David Carr, MD Today s Webcast Friday, 09/09/11, Noon 1 New Features Enlarge Slides Links Chapters Polling Use the email function to let
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More information